ORIC PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.07 USD | +5.22% |
|
-12.19% | -12.28% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,240 | 578.9 | 264.8 | 501.9 | 544.1 | - | - |
| Enterprise Value (EV) 1 | 1,240 | 578.9 | 264.8 | 266.8 | 277.1 | 391.1 | 544.1 |
| P/E ratio | -10.1 x | -7.1 x | -2.62 x | -4.69 x | -4.42 x | -4.08 x | -3.76 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 39.1 x |
| EV / Revenue | - | - | - | - | - | - | 39.1 x |
| EV / EBITDA | -16.9 x | -7.42 x | -2.92 x | -2.43 x | -2.18 x | -2.89 x | -4.22 x |
| EV / FCF | -27 x | -9.57 x | -3.43 x | -3.08 x | -3.55 x | -3.62 x | -3.65 x |
| FCF Yield | -3.7% | -10.4% | -29.2% | -32.4% | -28.1% | -27.6% | -27.4% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 36,634 | 39,382 | 44,953 | 54,552 | 67,422 | - | - |
| Reference price 2 | 33.85 | 14.70 | 5.890 | 9.200 | 8.070 | 8.070 | 8.070 |
| Announcement Date | 3/23/21 | 3/21/22 | 3/16/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 13.9 |
| EBITDA 1 | - | -73.22 | -77.97 | -90.8 | -109.7 | -127.3 | -135.3 | -129 |
| EBIT 1 | -28.57 | -74.19 | -78.87 | -91.77 | -110.8 | -131.5 | -153.9 | -174.6 |
| Operating Margin | - | - | - | - | - | - | - | -1,255.97% |
| Earnings before Tax (EBT) 1 | - | -73.7 | -78.72 | -89.12 | -100.7 | -122.5 | -147.3 | -167.4 |
| Net income 1 | - | -73.7 | -78.72 | -89.12 | -100.7 | -122.5 | -147.7 | -167.4 |
| Net margin | - | - | - | - | - | - | - | -1,203.57% |
| EPS 2 | - | -3.360 | -2.070 | -2.250 | -1.960 | -1.827 | -1.978 | -2.146 |
| Free Cash Flow 1 | - | -45.94 | -60.48 | -77.22 | -86.54 | -78 | -108 | -149 |
| FCF margin | - | - | - | - | - | - | - | -1,071.58% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 3/23/21 | 3/21/22 | 3/16/23 | 3/11/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | -18.24 | - | - | - | - | -21.87 | -25.42 | -24.73 | -28.42 | -31.16 | -30.99 | -31.8 | -32.11 | -32.44 | - |
| EBIT 1 | -18.46 | -22.8 | -23.26 | -20.7 | -25.69 | -22.12 | -25.68 | -24.99 | -28.68 | -31.43 | -31.57 | -32.28 | -33.53 | -34.14 | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -18.43 | -22.77 | -23.16 | -20.29 | -24.83 | -20.85 | -23.94 | -22.94 | -25.48 | -28.33 | -29.28 | -29.7 | -31.29 | -32.25 | - |
| Net income 1 | -18.43 | -22.77 | -23.16 | -20.29 | -24.83 | -20.85 | -23.94 | -22.94 | -25.48 | -28.33 | -29.28 | -29.7 | -31.29 | -32.25 | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.4700 | -0.5800 | -0.5900 | -0.5100 | -0.6300 | -0.5200 | -0.5300 | -0.5000 | -0.4400 | -0.4900 | -0.4358 | -0.4308 | -0.4500 | -0.4660 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/21/22 | 5/9/22 | 8/11/22 | 11/7/22 | 3/16/23 | 5/8/23 | 8/10/23 | 11/6/23 | 3/11/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 235 | 267 | 153 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -45.9 | -60.5 | -77.2 | -86.5 | -78 | -108 | -149 |
| ROE (net income / shareholders' equity) | -39% | -28% | -36% | -45.1% | -56.5% | -49.9% | -46.2% |
| ROA (Net income/ Total Assets) | -37.5% | -26.3% | -32.7% | -40.3% | -44.9% | -40.2% | - |
| Assets 1 | 196.5 | 298.8 | 272.9 | 249.6 | 273.1 | 367.4 | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 0.67 | 0.94 | 2.08 | 0.85 | - | 0.5 | 1 |
| Capex / Sales | - | - | - | - | - | - | 7.19% |
| Announcement Date | 3/23/21 | 3/21/22 | 3/16/23 | 3/11/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.07
USD
Average target price
19
USD
Spread / Average Target
+135.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.28% | 544M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ORIC Stock
- Financials ORIC Pharmaceuticals, Inc.
